Co Agonists At Glp 1 And Gip Receptors Suitable For Oral Delivery

Abstract: Peptide co-agonists of the human GLP-1 and GIP receptors suitable for oral delivery, including long-acting derivatives, and their medical use in treatment and/or prevention of obesity, diabetes, and/or liver diseases are described.

Patent Information

Application #

Filing Date

06 February 2023

Publication Number

06/2023

Publication Type

INA

Invention Field

BIO-CHEMISTRY

Status

Email

NNCP-IN@novonordisk.com

Parent Application

Applicants

NOVO NORDISK A/S

Novo Allé 2880 Bagsværd

Inventors

1. KNERR, Patrick, J.

46168 Plainfield Indiana

2. FINAN, Brian

46220 Indianapolis Indiana

3. DIMARCHI, Richard

46033 Carmel Indiana

4. LINDEROTH, Lars

Novo Allé 2880 Bagsværd

Specification

Documents

Application Documents

#	Name	Date
1	202347007342.pdf	2023-02-06
2	202347007342-STATEMENT OF UNDERTAKING (FORM 3) [06-02-2023(online)].pdf	2023-02-06
3	202347007342-Sequence Listing in txt [06-02-2023(online)].txt	2023-02-06
4	202347007342-Sequence Listing in PDF [06-02-2023(online)].pdf	2023-02-06
5	202347007342-PRIORITY DOCUMENTS [06-02-2023(online)].pdf	2023-02-06
6	202347007342-POWER OF AUTHORITY [06-02-2023(online)].pdf	2023-02-06
7	202347007342-FORM 1 [06-02-2023(online)].pdf	2023-02-06
8	202347007342-DECLARATION OF INVENTORSHIP (FORM 5) [06-02-2023(online)].pdf	2023-02-06
9	202347007342-COMPLETE SPECIFICATION [06-02-2023(online)].pdf	2023-02-06
10	202347007342-FORM 18 [07-02-2023(online)].pdf	2023-02-07
11	202347007342-FORM 3 [31-07-2023(online)].pdf	2023-07-31
12	202347007342-Proof of Right [04-08-2023(online)].pdf	2023-08-04
13	202347007342-FORM-26 [25-10-2023(online)].pdf	2023-10-25
14	202347007342-FORM 3 [25-01-2024(online)].pdf	2024-01-25